FDG-PET is valuable for the assessment of recurrent colorectal carcinoma, according to a meta-analysis in the January issue of the International Journal of Cancer.
Gang Huang, MD from the department of nuclear medicine at Renji hospital, Shanghai Jiaotong University School of Medicine in Shanghai, China, and colleagues sought to evaluate the diagnostic value of PET using fluor-18-deoxyglucose (FDG) in recurrent colorectal carcinoma in a meta-analysis of 27 trials.
According to the researchers, the pooled sensitivity and specificity for FDG-PET detecting distant metastasis or whole body involvement in recurrent colorectal carcinoma were 0.91 and 0.83, respectively.
They also found that the pooled sensitivity and specificity for FDG-PET detecting hepatic metastasis were 0.97 and 0.98. The pooled sensitivity and specificity for pelvic metastasis or local regional recurrence were 0.94 and 0.9.
As a result of their findings, the authors concluded that “FDG-PET is valuable for the assessment of recurrent colorectal carcinoma.”